The document discusses a webinar that took place on July 8th, 2014 about Alzheimer's disease. It notes that gene variants with the highest functional impact may not necessarily show the strongest association with disease risk. It also mentions that cerebrospinal fluid TREM2 levels could be a better biomarker than plasma levels and questions whether any other variants could affect CSF TREM2 levels or if different TREM2 alternative transcripts play a role in its function and pathogenesis.

1. AlzforumWebinar
July 8th. 2014

2.  The variants with the highest functional
impact, do not need to show the most
significant association with disease risk
 CSF TREM2 levels  better biomarker than
plasma levels
 Is there any other variant (cis/trans) that affect
CSF TREM2 levels?
 Does the different TREM2 alternative
transcript play a role in TREM2
function/pathogenesis?